APP and early-onset autosomal dominant Alzheimer disease: These data suggest that, as DCA is a small molecule able to traverse the blood-brain-barrier, further research into its mechanism of action with respect to APP proteolysis may lead to the development of therapies for slowing the progression of Alzheimer’s disease.